← Eichor
Condition: R R Aml Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: R R Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Phase 1 · 11 location(s) · AvenCell Europe GmbH · NCT05949125BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 · 1 location(s) · Eric Stephen Winer, MD · NCT05703542Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 2 location(s) · iCell Gene Therapeutics · NCT07668557Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Pacylex Pharmaceuticals · NCT06613217Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07144020Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 · 106 location(s) · Kura Oncology, Inc. · NCT07007312Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07617285A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT06741722A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Phase 3 · 53 location(s) · Hutchmed · NCT06387069Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06621212Study of IBR733 Cell Injection in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Imbioray (Hangzhou) Biomedicine Co., Ltd. · NCT06234904Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
Phase 1 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06737523Off-the-shelf CD123 CAR-NK for R/R AML
EARLY_Phase 1 · 1 location(s) · Peking University People's Hospital · NCT06201247Tazemetostat and Palbociclib With CPX-351for R/R AML
Phase 1 · 1 location(s) · Thomas Jefferson University · NCT05627232HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Phase 3 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT05586074Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
Phase 1 · 1 location(s) · Hemogenyx Pharmaceuticals LLC · NCT06786533Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Phase 1/Phase 2 · 3 location(s) · ARCE Therapeutics, Inc. · NCT06680752Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT05305859A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Phase 1 · 13 location(s) · BlossomHill Therapeutics · NCT06501196Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractor
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT02390752A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 8 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05924750Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Phase 2 · 2 location(s) · ETH Zurich · NCT06138990Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
Phase 2 · 10 location(s) · Changzhou Qianhong Bio-pharma Co., Ltd. · NCT06532058Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Phase 1 · 13 location(s) · Oryzon Genomics S.A. · NCT05546580A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06879847CAV Regimen for R/R AML
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05657639Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic
Phase 1/Phase 2 · 2 location(s) · Gyala Therapeutics · NCT07471789A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07500753
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.